U.S. Sales Force Hired and Trained with U.S Launch of Jeuveau™ Imminent NEWPORT BEACH, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results

IRVINE, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that members of management will be participating in two upcoming investor conferences.

European Commission Approval Anticipated Within 90 Days NEWPORT BEACH, Calif. , April 26, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the European Medicines Agency’s

IRVINE, Calif. , April 24, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will release first quarter 2019 financial results and provide a business update after

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 87.2% for Jeuveau™, 82.8% for BOTOX ® and 4.2% for Placebo at Day 30 Secondary and Exploratory Analyses Unveil Additional Information about Jeuveau™ Clinical Performance  Thirty New Exploratory Head-to-Head Data Points Conference

NEWPORT BEACH, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it expects the European Medicines Agency (EMA) Committee for Medicinal Products for

First Peer-Reviewed Publication from TRANSPARENCY Global Clinical Program Further Validates Safety and Efficacy of Jeuveau™ vs Placebo NEWPORT BEACH, Calif. , March 21, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on

Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8 th , 2019 in New York, NY NEWPORT BEACH, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc.

Provides Non-Dilutive Financing and Increased Flexibility Ahead of Jeuveau™ U.S. Launch NEWPORT BEACH, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced

IRVINE, Calif. , March 15, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will release fourth quarter and full year 2018 financial results and provide a business